Compare AKR & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AKR | CDNA |
|---|---|---|
| Founded | 1993 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.6B |
| IPO Year | 1996 | 2007 |
| Metric | AKR | CDNA |
|---|---|---|
| Price | $19.58 | $52.93 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | $22.25 | ★ $28.00 |
| AVG Volume (30 Days) | ★ 1.2M | 1.1M |
| Earning Date | 04-28-2026 | 04-28-2026 |
| Dividend Yield | ★ 3.69% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.27 | ★ 2.13 |
| Revenue | ★ $410,757,000.00 | $48,324,000.00 |
| Revenue This Year | $3.21 | $16.01 |
| Revenue Next Year | $12.17 | $11.31 |
| P/E Ratio | $72.74 | ★ $24.71 |
| Revenue Growth | 14.20 | ★ 18.93 |
| 52 Week Low | $18.61 | $13.72 |
| 52 Week High | $23.03 | $53.67 |
| Indicator | AKR | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 28.35 | 67.90 |
| Support Level | $19.38 | $45.74 |
| Resistance Level | $21.29 | $53.67 |
| Average True Range (ATR) | 0.36 | 2.36 |
| MACD | -0.07 | -0.24 |
| Stochastic Oscillator | 1.20 | 84.40 |
Acadia Realty Trust is a real estate investment trust that specializes in the operation, management, leasing, renovation, and acquisition of shopping centers and mixed-use properties with retail components. The company operates through three segments: REIT Portfolio segment consists of high-quality retail properties located in high-barrier-to-entry, densely-populated metropolitan areas with a long-term investment horizon; Investment Management segment holds the retail real estate in which the company co-invests with high-quality institutional investors; and Structured Financing segment consists of earnings and expenses related to notes and mortgages receivable Fees earned by the company as the general partner or managing member through Investment Management.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.